An enzyme from fermented soybeans that helps break down blood clots. Its most dependable benefit is a modest lowering of blood pressure, alongside a shift toward easier clot breakdown. Artery-hardening and cholesterol claims conflict between studies. The main downside is added bleeding risk, especially with blood thinners or around surgery. The evidence base remains unsettled and often industry-funded. (Full Review)

Protocol

Standard Dose

100 mg (2,000 FU) daily

Most widely used and clinically studied regimen; taken once daily.

Timing

At night, empty stomach

Clots more often form at night; away from a meal may aid absorption.

Higher-Dose Approach

10,800 FU daily

Alternative regimen argued for lipid and atherosclerosis effects; often split into two doses.

Time to effect

Blood Pressure

~8 weeks

Reductions emerged over roughly eight weeks of daily use.

Clotting Markers

~2 months

Fibrinogen and clotting factors fell over about two months.

Fibrinolytic Activity

8–12 hours

Per-dose effect peaks within a few hours and persists roughly 8–12 hours.

Benefits

Medium: Blood pressure reduction; antithrombotic and fibrinolytic support

Low: Atherosclerosis and arterial health; lipid profile improvement

Speculative: Anti-inflammatory and antioxidant effects; cognitive and cerebral blood flow support

Contraindications

Bleeding disorders

Active peptic ulcer

Recent hemorrhagic stroke (within ~90 days)

Planned surgery (within ~2 weeks)

Pregnancy or breastfeeding

Soy allergy

Anticoagulant or antiplatelet therapy (without supervision)

Key Interactions

Prescription anticoagulants (warfarin; DOACs: apixaban, rivaroxaban, dabigatran)

Antiplatelet or thrombolytic drugs (clopidogrel)

OTC pain relievers (aspirin, NSAIDs such as ibuprofen)

Blood-thinning supplements (fish oil, garlic, Ginkgo biloba, vitamin E, curcumin, ginger, policosanol, pine-bark extract)

Antihypertensive drugs and blood-pressure-lowering supplements

Vitamin K2 (opposes warfarin; usually removed from purified products)

Risk & Side Effects

Medium: Bleeding and enhanced anticoagulation

Low: Allergic reactions and anaphylaxis; gastrointestinal discomfort; blood glucose elevation

Monitoring

Marker	Target	Why
Blood pressure	<120/80 mmHg	Primary trackable benefit
Fibrinogen	200–300 mg/dL	Clot-forming protein the enzyme targets
D-dimer	<0.5 µg/mL	Reflects clot formation and breakdown
PT / INR	INR near 1.0 (if not on anticoagulants)	Bleeding-risk and clotting-time safety check
LDL cholesterol	<100 mg/dL (lower if high-risk)	Tracks the contested lipid effect
hs-CRP	<1.0 mg/L	Inflammation linked to vascular risk
Carotid intima-media thickness (CIMT)	Below age/sex reference; no plaque	Tracks arterial-wall changes if that is the goal

Cadence: Recheck blood pressure at ~4 and 8 weeks, then every 3–6 months; recheck clotting parameters within 1–2 weeks if on an interacting drug, then every 6–12 months otherwise.

Qualitative Assessment

Stable or improved home blood-pressure readings
Absence of unusual bruising or bleeding
General sense of well-being and energy without side effects
No digestive discomfort over time

Nattokinase for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment